Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2016 Jan 16;87(3):259-265.

Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy

Francesco Di Pierro  1 , Annamaria Parolari, Benedetta Brundu, Raffaele Nigro
Affiliations
Controlled Clinical Trial

Positive clinical outcomes derived from using a proprietary mixture of selected strains during pregnancy

Francesco Di Pierro et al. Acta Biomed. .

Abstract

Background: While the use of antibiotic prophylaxis is clearly advantageous to prevent streptococcal infection, it alters the composition of the gut microbiota in mothers and infants. Enterococcus faecium L3 is one of the best studied probiotic strains and shows strong antagonistic activity against Streptococcus agalactiae due to the production of bacteriocins able to inhibit common gut and vaginal pathogens.

Methods: We tested an L3-based probiotic formula (iNatal®) on 127 pregnant women attending our gynaecological unit in 2015. We compared the study subjects with 279 pregnant women enrolled in the same year and with 892 other pregnant women who attended our gynaecological unit in 2013 and 2014.

Results: The findings demonstrate: (a) the safety profile of the product; (b) its ability to reduce gut disorders; (c) a 6% decrease in the incidence of streptococcal colonization; (d) an approximately 30% decline in episodes of premature rupture of membranes; (e) fewer caesarean sections during labour; and (f) a reduction in pathological umbilical cord blood pH.

Conclusions: Our results demonstrate that a probiotic treatment during pregnancy could have unexpected but favourable clinical results. Further randomized, double-blind, placebo controlled studies are now needed to confirm our preliminary findings.

Keywords: Enterococcus faecium L3; Intrapartum Antibiotic Prophylaxis; PROM; Streptococcus agalactiae; iNatal..

PubMed Disclaimer

Conflict of interest statement

FDP is a member of the scientific council of a company selling iNatal®. The other authors have no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol. 2006;4:932–42. - PMC - PubMed
    1. Rivera L, Sáez-Llorens X, Feris-Iglesias J, et al. Incidence and serotype distribution of invasive group B streptococcal disease in young infants: a multi-country observational study. BMC Pediatr. 2015;15:143–49. - PMC - PubMed
    1. Mazzola G, Murphy K, Ross RP, et al. Early gut microbiota perturbations following intrapartum antibiotic prophylaxis to prevent Group B streptococcal disease. PLoS One. 2016;11(6):e0157527. - PMC - PubMed
    1. Barthow C, Wickens K, Stanley T, et al. The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. BMC Pregnancy Childbirth. 2016;16(1):133. - PMC - PubMed
    1. Ermolenko EI, Chernysh AI, Martsinkovskaia IV, Suvorov AN. Influence of probiotic enterococci on the growth of Streptococcus agalactiae. Zh Mikrobiol Epidemiol Immunobiol. 2007;(5):73–7. - PubMed

Publication types